NASDAQ:NCNA NuCana (NCNA) Stock Forecast, Price & News $0.62 -0.03 (-4.62%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$0.60▼$0.6550-Day Range$0.61▼$0.8552-Week Range$0.59▼$1.75Volume23,178 shsAverage Volume84,223 shsMarket Capitalization$32.18 millionP/E RatioN/ADividend YieldN/APrice Target$3.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media NuCana MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside504.8% Upside$3.75 Price TargetShort InterestHealthy0.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.64Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.58) to ($0.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.39 out of 5 starsMedical Sector218th out of 961 stocksPharmaceutical Preparations Industry93rd out of 448 stocks 3.5 Analyst's Opinion Consensus RatingNuCana has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.75, NuCana has a forecasted upside of 504.8% from its current price of $0.62.Amount of Analyst CoverageNuCana has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.13% of the float of NuCana has been sold short.Short Interest Ratio / Days to CoverNuCana has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NuCana has recently decreased by 45.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuCana does not currently pay a dividend.Dividend GrowthNuCana does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NCNA. Previous Next 1.9 News and Social Media Coverage News SentimentNuCana has a news sentiment score of -0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NuCana this week, compared to 0 articles on an average week.Search Interest4 people have searched for NCNA on MarketBeat in the last 30 days. MarketBeat Follows1 people have added NuCana to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NuCana insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 26.54% of the stock of NuCana is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NuCana are expected to grow in the coming year, from ($0.58) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NuCana is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NuCana is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuCana has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NuCana (NASDAQ:NCNA) StockNuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, which is in a Phase 1b/2 study in patients with metastatic colorectal cancer. The company also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer; and initiated a Phase 1b/2 modular study of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. Its pipeline also comprises NUC-7738, a transformation of 3'-deoxyadenosine that is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Read More NCNA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NCNA Stock News HeadlinesSeptember 18, 2023 | finanznachrichten.deNuCana plc: NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023September 18, 2023 | finance.yahoo.comNuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023September 21, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 7, 2023 | msn.comTruist Securities Reiterates NuCana plc - ADR (NCNA) Buy RecommendationAugust 17, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Again ThursdayAugust 17, 2023 | msn.comNuCana Q2 Earnings: Recent Updates Bode Poorly, Not Worth The RiskAugust 16, 2023 | finanznachrichten.deNuCana plc: NuCana Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 16, 2023 | finance.yahoo.comNuCana Reports Second Quarter 2023 Financial Results and Provides Business UpdateSeptember 21, 2023 | Chaikin Analytics (Ad)Get Your Cash Out of U.S. Banks ImmediatelyMan who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.August 9, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Lower WednesdayJuly 25, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise TuesdayJuly 24, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Start Week Moving LowerJuly 10, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Open Week HigherJuly 6, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Tumble ThursdayJuly 3, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Start Week Off Lower MondayJune 1, 2023 | finanznachrichten.deNuCana plc: NuCana to Present at the Jefferies Healthcare ConferenceJune 1, 2023 | finance.yahoo.comNuCana to Present at the Jefferies Healthcare ConferenceMay 22, 2023 | msn.comOppenheimer Reiterates NuCana plc - ADR (NCNA) Outperform RecommendationMay 17, 2023 | finanznachrichten.deNuCana plc: NuCana Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 17, 2023 | finance.yahoo.comNuCana Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 14, 2023 | marketwatch.comNuCana Receives Notices That ADSs Don't Satisfy Nasdaq Listing RequirementsApril 15, 2023 | finanznachrichten.deNuCana plc: NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of ActionApril 14, 2023 | finance.yahoo.comNuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of ActionApril 4, 2023 | finance.yahoo.comNuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business UpdateMarch 24, 2023 | finance.yahoo.comTechnical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not ValidMarch 24, 2023 | finance.yahoo.comWe're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn RateMarch 14, 2023 | msn.comBank Stocks Boost European Equities Sharply Higher in Tuesday TradingSee More Headlines Receive NCNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter. Email Address NCNA Company Calendar Last Earnings8/16/2023Today9/21/2023Next Earnings (Estimated)11/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NCNA CUSIPN/A CIK1709626 Webwww.nucana.com Phone441313571111FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.75 High Stock Price Forecast$6.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+504.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-86.57% Return on Assets-59.91% Debt Debt-to-Equity RatioN/A Current Ratio2.80 Quick Ratio2.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book0.68Miscellaneous Outstanding Shares51,900,000Free Float35,709,000Market Cap$32.18 million OptionableNot Optionable Beta1.15 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Hugh Stephen Griffith (Age 55)Founder, CEO & Exec. Director Comp: $1.27MMr. Donald Munoz (Age 54)Chief Financial Officer Mr. David Harrison (Age 64)Head of Translational Medicine Prof. Christopher B. Wood FRCS (Age 77)M.D., Ph.D., Chief Medical Officer Ms. Theresa BruceSr. VP of Clinical OperationsMs. Elisabeth OelmannSr. VP of Medical & Clinical Devel.Dr. Jeffrey D. Bloss F.A.C.O.G. (Age 66)M.D., Chief Medical Officer Martin QuinnCompany Sec.More ExecutivesKey CompetitorsBeyondSpringNASDAQ:BYSIIndaptus TherapeuticsNASDAQ:INDPRegulus TherapeuticsNASDAQ:RGLSASLAN PharmaceuticalsNASDAQ:ASLNNeoleukin TherapeuticsNASDAQ:NLTXView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCBought 26,900 shares on 8/11/2023Ownership: 0.708%View All Institutional Transactions NCNA Stock - Frequently Asked Questions Should I buy or sell NuCana stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NCNA shares. View NCNA analyst ratings or view top-rated stocks. What is NuCana's stock price forecast for 2023? 3 brokerages have issued twelve-month target prices for NuCana's stock. Their NCNA share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's stock price to reach $3.75 in the next year. This suggests a possible upside of 504.8% from the stock's current price. View analysts price targets for NCNA or view top-rated stocks among Wall Street analysts. How have NCNA shares performed in 2023? NuCana's stock was trading at $0.66 on January 1st, 2023. Since then, NCNA stock has decreased by 6.1% and is now trading at $0.62. View the best growth stocks for 2023 here. Are investors shorting NuCana? NuCana saw a decline in short interest in August. As of August 31st, there was short interest totaling 55,100 shares, a decline of 45.5% from the August 15th total of 101,100 shares. Based on an average daily trading volume, of 49,300 shares, the days-to-cover ratio is presently 1.1 days. Currently, 0.1% of the company's shares are short sold. View NuCana's Short Interest. When is NuCana's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 15th 2023. View our NCNA earnings forecast. How were NuCana's earnings last quarter? NuCana plc (NASDAQ:NCNA) announced its quarterly earnings results on Wednesday, August, 16th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. What other stocks do shareholders of NuCana own? Based on aggregate information from My MarketBeat watchlists, some companies that other NuCana investors own include Wirecard (WDI), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Ovid Therapeutics (OVID), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Pfizer (PFE), Rigel Pharmaceuticals (RIGL) and Tetraphase Pharmaceuticals (TTPH). When did NuCana IPO? (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager. What is NuCana's stock symbol? NuCana trades on the NASDAQ under the ticker symbol "NCNA." Who are NuCana's major shareholders? NuCana's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.71%). How do I buy shares of NuCana? Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NuCana's stock price today? One share of NCNA stock can currently be purchased for approximately $0.62. How much money does NuCana make? NuCana (NASDAQ:NCNA) has a market capitalization of $32.18 million. The company earns $-39,610,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. How can I contact NuCana? NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The official website for the company is www.nucana.com. The company can be reached via phone at 441313571111 or via email at chris.brinzey@westwicke.com. This page (NASDAQ:NCNA) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.